Finland· FI-REL-REL7044

Acordas

A sulfinpyrazone product, registered in Finland by MEDICA. The same ATC class is registered in 2 of our 19 countries.

ATC M04AB02

Checked against Fimea (Finland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about AcordasAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Sulfinpyrazone is registered in 2 of 19 countries.

Countries holding a registration under ATC M04AB02 (sulfinpyrazone), each read from that country’s own register.

This record: Finland, from Fimea (Finland)
1 of them publish a price we can compare per daily dose

Search sulfinpyrazone products by name

Sulfinpyrazone · ATC M04AB02

2 / 19 countries

Finlandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)

Manufacturer: MEDICA
Country: Finland (FI)
ATC code: M04AB02
ATC class: Sulfinpyrazone
Defined daily dose: 0.3 g, O
Reimbursed: Not published by this register
Source register: Fimea (Finland)
Last checked: September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

209 interactions on record for sulfinpyrazone.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check sulfinpyrazone against other medicines How interaction checks work

Sulfinpyrazone · interactions on record

209 records

31 severe
167 moderate
11 minor

Most severe, free to view

WarfarinB01AA03severe
DalteparinB01AB04severe
EnoxaparinB01AB05severe
CangrelorB01AC25severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under M04AB02

Sulfinpyrazone, as other registers publish it.

All sulfinpyrazone products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/b066bf1e-a959-42b3-b1ae-319c9d2d2a92
GET /v1/drugs/b066bf1e-a959-42b3-b1ae-319c9d2d2a92?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.3",
  "form": "tabletti",
  "route": null,
  "ddd_unit": "g",
  "strength": "200 mg",
  "atc_label": "sulfiinipyratsoni",
  "ma_number": "8988",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL7044",
  "authorised_at": "1985-03-20"
}

API reference MCP server Plans

See everything about sulfinpyrazone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console